American researchers have developed an RNA-based platform that uses CRISPR epigenetic editors to durably silence or activate genes in primary human T...

Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...

Feng Zhang and colleagues report that the engineering of a compact RNA-guided nuclease, NovaIscB, derived from the OMEGA system enables efficient and...

Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...

Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...

Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...

In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...